Quimioprevención del cáncer de mama
| Autor: | J. E. Alés Martínez |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Drug
Oncology medicine.medical_specialty medicine.medical_treatment media_common.quotation_subject Breast cancer mortality Population Quimioprevención Breast cancer Cáncer de mama Internal medicine Medicine Tamoxifeno Aromatase education media_common Female population Gynecology education.field_of_study biology business.industry medicine.disease Selective estrogen receptor modulator biology.protein Anastrozol business ExCel Adjuvant Exemestano |
| Zdroj: | Oncología (Barcelona) v.29 n.1 2006 SciELO España. Revistas Científicas Españolas de Ciencias de la Salud instname |
| Popis: | The pharmacological prevention (chemoprevention) of breast cancer is the new challenge of modern medical oncology to deal with a kind of tumor that is the most frequent among the female population all over the world. The extension of the screening programs for early-stage detection and the advances in therapeutic pharmacology have achieved a continued reduction in breast cancer mortality in the last decade. However, the incidence rate continues increasing or is at least stable, what considered together with the increasing proportion of women in follow-up after completing the adjuvant treatment, leads to a continued increase of the medical and social burden of breast cancer. For this reason, the securing of an efficacious, safe and tolerated drug diminishing the tumor incidence is a very desirable objective. Presently, once demonstrated that tamoxifen-mediated estrogenic inhibition can prevent the appearance of breast cancer, the research of the role of other SERMs (Selective Estrogen Receptor Modulators) and aromatase inhibitors is very active, looking for products having a favorable risk-benefit ratio that will make then useful for wide groups of population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|